Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer

Yuan, Zhi; Zhou, Wen; Liu, Wei; Wu, Bai Ping; Zhao, Jin; Wu, Wei; He, Yi; Yang, Shuo; Su, Jing; Luo, Yi

doi:10.7314/apjcp.2015.16.10.4347

Cited by 13 publications

(19 citation statements)

References 24 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study characteristics of the 28 articles included, all were candidate gene studies published between 2008 and 2017, are shown in Table 1 . Most were cohort studies (Wang et al, 2008 ; Filipski et al, 2009 ; Goekkurt et al, 2009 ; Chen et al, 2010 ; Khrunin et al, 2010a , 2012 , 2014 ; KimCurran et al, 2011 ; Tzvetkov et al, 2011 ; Erculj et al, 2012 ; Iwata et al, 2012 ; Windsor et al, 2012 ; Xu et al, 2012 , 2013 ; Zhang and Zhou, 2012 ; Zhang et al, 2012 ; Hinai et al, 2013 ; Khokhrin et al, 2013 ; Lamba et al, 2014 ; Yuan et al, 2015 ; Hattinger et al, 2016 ; Powrozek et al, 2016 ; Chang et al, 2017 ) and none were genome wide association studies (GWAS). Key details of subject characteristics [e.g., ethnicity and inclusion criteria (Sprowl et al, 2012 )], type of chemotherapy regimens (Erculj et al, 2012 ; Sprowl et al, 2012 ; Powrozek et al, 2016 ), and nephrotoxicity criteria (Goekkurt et al, 2009 ; Kim et al, 2012 ; Khrunin et al, 2014 ) were not reported in some studies.…”

Section: Resultsmentioning

confidence: 99%

Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review

et al. 2018

View full text Add to dashboard Cite

Background: Nephrotoxicity is a notable adverse effect in cisplatin treated patients characterized by tubular injury and/or increased serum creatinine (SCr) with incidence varying from 20 to 70%. Pharmacogenomics has been shown to identify strongly predictive genetic markers to help determine which patients are more likely to experience, for example, a serious adverse drug reaction or receive optimal benefit through enhanced efficacy. Genetic variations have been reported to influence the risk of cisplatin nephrotoxicity; however, a comprehensive overview is lacking.Methods: A systematic review was performed using Pubmed, Embase and Web of Science on clinical studies that used cisplatin-based chemotherapy as treatment, had available genotyping data, and evaluated nephrotoxicity as an outcome. The quality of reporting was assessed using the STrengthening the REporting of Genetic Association Studies (STREGA) checklist.Results: Twenty-eight eligible studies were included; all were candidate gene studies. Over 300 SNPs across 135 genes were studied; 29 SNPs in 14 genes were significantly associated with cisplatin-induced nephrotoxicity. A variation in SLC22A2 rs316019, a gene involved in platinum uptake by the kidney, was associated with different measures of nephrotoxicity in four independent studies. Further, variants of ERCC1 (rs11615 and rs3212986) and ERCC2 (rs13181), two genes involved in DNA repair, were found to be positively associated with increased risks of nephrotoxicity in two independent studies.Conclusion: Three genes consistently associated with cisplatin-induced nephrotoxicity. Further research is needed to assess the biological mechanism and the clinical value of modifying treatment based on SLCC22A2 and ERCC1/2 genotypes.

show abstract

Section: Resultsmentioning

confidence: 99%

Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The Newcastle-Ottawa Scale (NOS) was used to evaluated the quality of these included studies, based on a scoring system with three components: the selection of the subjects (0–4 points); the comparability of the study groups (0–2 points); the determination of the outcome of interest (treatment response) (0–3 points). The highest NOS score for each publication was 9 points, and in this meta-analysis, two studies had a NOS score of 9 [ 11 , 31 ]; 11 studies had a NOS score of 8 [ 8 – 10 , 12 , 13 , 15 , 16 , 20 , 25 , 26 , 30 ]; eight studies had a NOS score of 7 [ 2 , 7 , 14 , 19 , 21 , 24 , 28 , 29 ]; and two studies had a NOS score of 6 [ 23 , 27 ].…”

Section: Resultsmentioning

confidence: 99%

Glutathione S-Transferase Gene Polymorphisms are Associated with an Improved Treatment Response to Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

BackgroundPrevious studies have shown an association with glutathione S-transferase (GST) gene polymorphisms in patients with non-small cell lung cancer (NSCLC) and treatment response. This study aimed to undertake a literature review and meta-analysis of GST gene polymorphisms, including GSTT1, GSTM1, and GSTP1 IIe105Val, and the treatment response to cisplatin-based chemotherapy in patients with NSCLC.Material/MethodsA literature search was undertaken of the main medical publication databases for publications, up to March 2017, on the association between GSTT1, GSTM1, and GSTP1 IIe105Val polymorphisms and the clinical outcome in patients with NSCLC treated with cisplatin-based chemotherapy. A random fixed-effects model was used to calculate the pooled odds ratio (OR) and 95% confidence interval (CI) to evaluate the associations, considering multiple genetic models. A subgroup analysis according to ethnicity was performed.ResultsTwenty-three published studies were identified that showed that both the null GSTM1 and the GG genotype of GSTP1 IIe105Val were associated with improved treatment response to cisplatin-based chemotherapy (GSTT1 present/null: OR=1.328; 95% CI, 1.074–1.643) (GSTP1 GG + AG vs. AA: OR=0.596; 95% CI, 0.468–0.759). In subgroup analysis, the GSTP1 polymorphism was significantly associated with treatment response in East-Asian patients, but not in Caucasian patients.ConclusionsMeta-analysis showed that the GG genotype of GSTP1 IIe105Val and the null GSTM1 genotype were associated with an improved treatment response to cisplatin-based chemotherapy in patients with NSCLC, especially in East-Asian patients.

show abstract

“…(2015)Asian (China)246170/7664.3 (32–76)IIIA-IVDDP/CBP-basedOS, PFSPCR-RFLP XPG rs2296147 rs873601 113 Yuan, Z. J. (2015)Asian (China)4742/559 (29–74)III-IVDDP+GEMORDNA sequencing GSTP1 rs1695 114 Deng, J. H. (2015)Asian (China)9766/3157 (31–79)IIIB-IVDDP+GEM/NVP/TAX/DOCOR, PFSDNA pyrosequencing XRCC1 rs25487, GSTP1 rs1695 115 Shi, Z. H. (2015)Asian (China)240155/8561.5 (34–78)III-IVDDP+GEM/NVP/TAX/DOCOR, OSPCR-RFLP ERCC1 rs11615 rs3212986 rs2298881 116 Han, B. (2015)Asian (China)325116/209NRIIIB-IVDDP+GEM/NVP/TAX/DOCOR, OSPCR-RFLP XRCC1 rs25487 rs1799782 rs25489, GSTP1 rs1695 117 Li, P. (2015)Asian (China)14289/5362 (43–81)IIIB-IVDDP+NVPORPCR-RFLP XPD rs13181 rs1799793 118 Liu, J. Y.…”

Section: Resultsmentioning

confidence: 99%

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

Tan

Qiu

Zhu

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Data regarding genetic polymorphisms and platinum-based chemotherapy (PBC) treatment outcomes in patients with NSCLC are published at a growing pace, but the results are inconsistent. This meta-analysis integrated eligible candidate genes to better evaluate the pharmacogenetics of PBC in NSCLC patients. Relevant studies were retrieved from PubMed, Chinese National Knowledge Infrastructure and WANFANG databases. A total of 111 articles comprising 18,196 subjects were included for this study. The associations of genetic polymorphisms with treatment outcomes of PBC including overall response rate (ORR), overall survival (OS) and progression-free survival (PFS) were determined by analyzing the relative risk (RR), hazard ration (HR), corresponding 95% confidence interval (CI). Eleven polymorphisms in 9 genes, including ERCC1 rs11615 (OS), rs3212986 (ORR), XPA rs1800975 (ORR), XPD rs1052555 (OS, PFS), rs13181 (OS, PFS), XPG rs2296147 (OS), XRCC1 rs1799782 (ORR), XRCC3 rs861539 (ORR), GSTP1 rs1695 (ORR), MTHFR rs1801133 (ORR) and MDR1 rs1045642 (ORR), were found significantly associated with PBC treatment outcomes. These variants were mainly involved in DNA repair (EXCC1, XPA, XPD, XPG, XRCC1 and XRCC3), drug influx and efflux (MDR1), metabolism and detoxification (GSTP1) and DNA synthesis (MTHFR), and might be considered as potential prognostic biomarkers for assessing objective response and progression risk in NSCLC patients receiving platinum-based regimens.

show abstract

Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer

Cited by 13 publications

References 24 publications

Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review

Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review

Glutathione S-Transferase Gene Polymorphisms are Associated with an Improved Treatment Response to Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

Contact Info

Product

Resources

About